Pharming Group N.V., a specialty pharmaceutical company, develops and produces human therapeutic proteins for the treatment of rare diseases and unmet medical needs. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of angioedema attacks in patients with acute hereditary angioedema (HAE) in Europe, the United States, Israel, European Union countries, Norway, Iceland, and Liechtenstein. It also engages in the development of recombinant human C1 inhibitor for treating HAE attacks; and recombinant human factor VIII (rhFVIII), a natural human blood clotting factor for treating haemophilia A. The company has a strategic collaboration with Shanghai Institute of Pharmaceutical Industry for the development, manufacture, and commercialization of new products based on the Pharming technology platform; and a partnership agreement with the China State Institute of Pharmaceutical Industry for the development of rhFVIII for the treatment of Haemophilia A. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
White Paper Declaration

PHAR price history

interval date selector

agregation type selector

Date

Change

Chg%

Open

Min.

Max.

2022-09-30

1.478

-0.005

-0.34

1.483

1.472

1.493

2022-09-30

1.477

-0.050

-3.27

1.527

1.474

1.532

2022-09-30

1.52

-0.028

-1.81

1.548

1.516

1.58

2022-09-30

1.515

0.057

3.91

1.458

1.447

1.52

2022-09-30

1.442

-0.011

-0.76

1.453

1.441

1.474

2022-09-30

1.469

0.027

1.87

1.442

1.44

1.485

2022-09-30

1.446

-0.001

-0.07

1.447

1.414

1.469

2022-09-30

1.455

-0.010

-0.68

1.465

1.436

1.486

2022-09-30

1.406

-0.013

-0.92

1.419

1.376

1.439

2022-09-30

1.43

0.010

0.70

1.42

1.413

1.449

2022-09-30

1.454

0.013

0.90

1.441

1.464

2022-09-30

1.427

0.044

3.18

1.383

1.363

1.435

2022-09-30

1.396

0.021

1.53

1.375

1.346

1.405

Trade Pharming Group N.V. - PHAR stock price

The Power Of Leverage

PHAR price history